Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 2)

Link copied
Case Copied 76 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 2)
[2016] FCAFC 111

Appeal from: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) (2015) 113 IPR 191; [2015] FCA 634
File number: NSD 837 of 2015
Judges: BESANKO, NICHOLAS AND BEACH JJ
Date of judgment: 24 August 2016
Catchwords: PATENTS – appeal against decision of primary judge that appellants’ claims were invalid for lack of novelty and lack of inventive step – where primary judge held respondent would have infringed appellants’ claims had they been valid – where patent concerns carbostyril compound called aripiprazole and its use in treatment of schizophrenia – where primary judge held features of claims accretions to knowledge or arbitrary not sufficient to give rise to novelty – whether primary judge’s conclusions about novelty and inventive step based on a flawed construction of the claims – whether primary judge erred in not construing a feature as an essential feature or integer of a claim – whether primary judge erred in finding a feature arbitrary
Legislation: Patents Act 1990 (Cth) ss 7, 13, 117
Cases cited:

Actavis UK Ltd v Janssen Pharmaceuticals NV [2008] FSR 35

Actavis UK Ltd v Merck & Co Inc [2009] 1 WLR 1186

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Limited [2013] HCA 50; (2013) 304 ALR 1

Bristol-Myers Squibb v Baker Norton Pharmaceuticals Inc [1999] RPC 253

British Celanese, Ltd v Courtaulds, Ltd (1935) 52 RPC 171

EISAI/Second Medical Indication (G05/83) [1979-85] EPOR B241

Electric and Musical Industries, Ld and Boonton Research Corporation, Ltd v Lissen, Ltd and another (1939) 56 RPC 23

Fresenius Medical Care Australia Pty Ltd v Gambro Pty Ltd and Another [2005] FCAFC 220; (2005) 67 IPR 230

General Tire & Rubber Company v Firestone Tyre and Rubber Company Limited and Others [1972] RPC 457

Kinabalu Investments Pty Ltd v Barron and Rawson Pty Ltd [2008] FCAFC 178

Lockwood Security Products Pty Ltd v Doric Products Pty Ltd [No 2] [2007] HCA 21; (2007) 235 CLR 173

Martin v Scribal Proprietary Limited (1954) 92 CLR 17

MOBIL/Friction Reducing Additive (G02/88) [1990] EPOR 73

Osram Lamp Works Ld v Pope’s Electric Lamp Company Ld (1917) 34 RPC 369

Raychem Corporation’s Patents [1998] RPC 31

Root Quality Pty Ltd and Another v Root Control Technologies Pty Ltd and Others [2000] FCA 980; (2000) 49 IPR 225

Sartas No 1 v Koukourou & Partners Pty Ltd and Another (1994) 30 IPR 479

Blanco White TA, Patents for inventions and the protection of industrial designs (5th ed, Stevens, 1983)

Dates of hearing: 12 and 13 November 2015
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 179
Counsel for the Appellants: Mr AJL Bannon SC with Ms CL Cochrane and Mr BA Mee
Solicitor for the Appellants: Allens
Counsel for the Respondent: Mr AJ Ryan SC with Mr ADB Fox
Solicitor for the…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] FCAFC 111
Decision Date

CaseChat Overview and Summary

In the case of Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 2), the appellants, Otsuka Pharmaceutical Co Ltd and Otsuka Australia Pty Ltd, appealed against a decision of the primary judge that their patent claims were invalid for lack of novelty and lack of inventive step. The dispute involved a patent concerning a carbostyril compound called aripiprazole and its use in the treatment of schizophrenia. The primary judge concluded that the respondent, Generic Health Pty Ltd, would have infringed the patent if it had been valid. The key issues before the court were whether the primary judge's conclusions about the novelty and inventive step were based on a flawed construction of the claims, whether the primary judge erred in not construing a feature as an essential feature or integer of a claim, and whether the primary judge erred in finding a feature arbitrary.

The court examined the construction of the patent claims, specifically whether they should be characterised as product claims or method or process claims. The primary judge held that "method or process" were apt to describe the content and subject matter of the Swiss type claim, a conclusion that the court found to be consistent with relevant authorities. The court also considered the state of knowledge at the priority date and the evidence presented by both parties, including expert and lay evidence. The appellants argued that the primary judge's conclusions about novelty and inventive step were flawed, while the respondent maintained that the claims were not novel and lacked an inventive step. The court found that the primary judge had correctly considered the state of knowledge and evidence when reaching his conclusions.

The court ultimately dismissed the appeal, holding that the primary judge's conclusions about the validity of the patent claims were correct. The court also found that the primary judge had not erred in his construction of the claims or in his assessment of the features. As a result, the patent claims were invalid for lack of novelty and lack of inventive step. The court ordered that the appeal be dismissed and that the appellants pay the respondent's costs of the appeal.

Orders

Orders of the court

1. The appeal be dismissed.

2. The appellants pay the respondent’s costs of the appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

The primary judge considered whether an invention defined by a Swiss type claim is properly characterised as a product claim or as a method or process claim and, further, whether either of these characterisations are apt for a Swiss type claim. The appellants’ case before the primary judge was that Swiss type claims are process claims, whereas the respondent’s case was that they are neither method or process claims nor product claims. His Honour said that the words “method” and “process” were to be given their ordinary English signification, and that for the purpose of the question he was considering, there was no difference between the two. He reached the conclusion that “method or process” were apt to describe the content and subject matter of the Swiss type claim to which he had referred. He said that this approach accorded with the authorities which he identified (at [119]-[120]). The Medical and Scientific Evidence Each party put forward a considerable volume of expert evidence. There was also some lay evidence, but it is not necessary to refer to that evidence for the purposes of the appeal. The appellants called Professor Bruce Sugriv Singh who swore four affidavits, Associate Professor Jonathan Phillips who swore one affidavit, and Associate Professor Trevor Ronald Norman who swore three affidavits. Professor Singh is a consultant psychiatrist in private practice at the Melbourne Clinic and a senior consultant psychiatrist at the Royal Melbourne Hospital. He was Deputy Dean of the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne, where he has been a Professor of Psychiatry since 1991. He has been a Fellow of the Royal Australian and New Zealand College of Psychiatrists (“RANZCP”) since 1979. Associate Professor Phillips is a consultant psychiatrist in private practice. He is an Associate Professor at the University of New South Wales, the University of Adelaide and James Cook University. He is a Fellow of the RANZCP and was the President of the College from 1998 to 2000. Associate Professor Norman is an Associate Professor in the Department of Psychiatry at the University of Melbourne. He was an Adjunct Professor in the School of Behavioural Sciences at La Trobe University and President of the International Society for the Investigation of Stress from 2002 to 2004. The respondent called Professor Patrick Dennistoun McGorry who swore four affidavits, Dr Jeremy Francis O’Dea who swore six affidavits, and Professor Iain Stewart McGregor who swore one affidavit. Professor McGorry is a consultant psychiatrist and Professor of Youth Mental Health at the University of Melbourne. He is an Executive Director of the Orygen Youth Health Research Centre and has been a Fellow of the RANZCP since 1986. Dr O’Dea is a consultant psychiatrist in public and private practice and a Conjoint Lecturer in the School of Psychiatry at the University of New South Wales. He has been a Fellow of the RANZCP since 1991.

Decision

Reasons for decision

Associate Professor Norman has theorised that given the anatomical location of 5-HT1A receptors in the brain, alteration of the frequency of firing (modulating the tone) of 5-HT1A receptor-dependent neuronal activity might affect memory, cognition or both, and there is pre-clinical evidence suggesting that 5-HT1A-active drugs may enhance memory or cognition.CONCLUSIONS ON THE ASSOCIATION FEATURE CONSTRUCTION A number of matters may be noted in terms of the state of knowledge that could be attributed to the skilled addressee as at the priority date. First, although there was considerable knowledge of the operation of the serotonin system in the brain, the system was complex. 14 unique receptor subtypes had been identified which used serotonin as their neurotransmitter (the 5-HT series). But the precise function of the receptor and the subtypes was unclear. Second, four 5-HT receptor subtypes had been identified as being involved in cognitive function. But the association, let alone the precise mechanism, linking the 5-HT1A receptor subtype and cognition was unclear, save that this receptor subtype had a higher affinity for serotonin. Third, there was some evidence linking schizophrenia with alterations in the 5-HT1A receptor function, with the further hypothesised link to cognitive function. But the hypothesis could not be said to be robust. The mechanism was unclear. Perhaps this might explain the nebulous language that “alterations in the 5-HT1A receptor are associated with cognitive impairment in schizophrenia” (Associate Professor Norman’s reply evidence). Fourth, it was a matter of speculation as to whether partial 5-HT1A agonists, such as aripiprazole, may be useful in the treatment of cognitive impairment in schizophrenia. Fifth, and relatedly, how speculative this all is can be demonstrated by the appellants’ reply evidence as at 13 June 2013 and a fortiori as at the priority date. Associate Professor Norman said at [10] to [12] in his affidavit of that date:The reason why I describe the proposition that partial 5-HT1A agonists may improve cognition as a “theory” is that it has not been conclusively proven that it is the 5-HT1A activity of these drugs which improve cognition and indeed, based on the current state of knowledge about the human brain, it would be impossible to “prove” a causal link between the 5-HT1A receptor and cognition because the brain is such a complex area and there is still so much unknown about how it works…Professor McGregor has criticised my evidence for use of the term “associated with” in the context of the link between the 5-HT1A receptor and cognition (at paragraph 45 of his affidavit) and the link between the 5-HT1A receptor and MDD (at paragraph 67 of his affidavit). I used the word “association” and “associated with” because, as noted above, there is no conclusive proof that the two are causally connected. However, based on the studies which find a change in a patient’s behaviour and/or physiological response (for example, hormone responses) after being treated with a drug which acts at that receptor, I believe it is appropriate to state that there is an “association” between that receptor and the behaviour/physiology, even if it is not currently possible to prove the causal connection between them.I am not aware of any drug available for clinical use which targets exclusively the 5-HT1A receptor. Accordingly, as all drugs which act at the 5-HT1A receptor also act as other receptors, it is not possible to conclusively prove that it is the 5-HT1A activity which brings about the physiological effect. Conversely, if a study purports to show that a 5-HT1A partial agonist drug does not improve cognition, it is impossible to conclude that there is no causal connection between the 5-HT1A receptor and cognitive improvement as it may be the effect of the drug at other receptors acting against the effects which may otherwise be caused as a result of the 5-HT1A activity.

Ratio Decidendi

Legal Principle Established